I don't know how many people follow Medmira, but they just got a US patent and the stock went from day low of .11 to around .40 on wednesday and yesterday went back to .21 and opened today at .205. They are having a conference call on monday. I think the stock should rise on monday so just wanted to inform you people but do your own due dilligence.

MedMira Invites Investment Analysts to Conference Call

HALIFAX, Jul 18, 2008 (Canada NewsWire via COMTEX) -- MMIRF | Quote | Chart | News | PowerRating -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF | Quote | Chart | News | PowerRating) a developer and marketer of rapid diagnostics, announced today that its president and CEO, Hermes Chan, will host a conference call with analysts to discuss the company's recent patent announcement and new growth opportunities for MedMira's rapid flow-through technology platform, beginning at 1:00 pm EST (2:00 pm AST) on Monday, July 21, 2008.

In order to listen to the conference call, please dial 1-800-732-9307 toll-free anywhere in Canada or the USA, or 1-416-644-3418 in the Toronto area.

A replay of the call will be available until 23:59 pm EST, Monday, July 28, 2008 and may be accessed by dialing 1-877-289-8525 toll-free anywhere in Canada or the USA, or 1-416-640-1917 in the Toronto area, and entering the pass code 21278759# anytime after the call has ended.

About MedMira

MedMira is a leading developer, manufacturer, and marketer of advanced rapid diagnostics. Built on the Company's patented rapid flow-through technology platform, MedMira's single and multiple rapid tests provide hospitals, labs, clinics and individuals around the world with reliable, diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets, have achieved regulatory approvals in Canada, the United States, China, Russia, India, and the European Union. MedMira is an approved supplier to US Agency for International Development (USAID) and the Pan American Health Organization (PAHO).

In 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on biosensor technology platforms. The new diagnostic solutions will enable routine laboratory tests to be performed in a matter of minutes, increasing automation, and streamlining the diagnosis of multiple conditions and diseases. Together MedMira and Maple Biosciences will be leading participants in the emerging fields of personalized medicine and molecular diagnostics. For more information visit www.maplebio.com.

MedMira's corporate offices, R&D, and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00013053E